{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T19:08:31Z","timestamp":1795115311205,"version":"4.10.3"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10549-025-07785-5","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T04:35:57Z","timestamp":1753677357000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Axillary dissection is avoidable in most cT1N0 triple-negative &amp; HER2+ breast cancers treated with upfront surgery"],"prefix":"10.1007","volume":"213","author":[{"given":"Anita","family":"Mamtani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varadan","family":"Sevilimedu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea V.","family":"Barrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"6","key":"7785_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R (2022) Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 20(6):691\u2013722. https:\/\/doi.org\/10.6004\/jnccn.2022.0030","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"7785_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134\u2013141. https:\/\/doi.org\/10.1056\/NEJMoa1406281","journal-title":"N Engl J Med"},{"issue":"5","key":"7785_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van\u2019t Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ (2020) Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. JAMA Oncol 6(5):676\u201384. https:\/\/doi.org\/10.1001\/jamaoncol.2019.6650","journal-title":"JAMA Oncol"},{"issue":"6","key":"7785_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier MA, Im SA, Ahn JH, Gion M, Baron-Hay S, Boileau JF, Ding Y, Tryfonidis K, Aktan G, Karantza V, O\u2019Shaughnessy J (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med 386(6):556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"issue":"9","key":"7785_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, K\u00fcmmel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"9","key":"7785_CR6","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, Tausch C, Seo JH, Tsai YF, Ratnayake J, McNally V, Ross G, Cort\u00e9s J (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"issue":"3","key":"7785_CR7","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1093\/annonc\/mdx773","volume":"29","author":"SM Swain","year":"2018","unstructured":"Swain SM, Ewer MS, Viale G, Delaloge S, Ferrero JM, Verrill M, Colomer R, Vieira C, Werner TL, Douthwaite H, Bradley D, Waldron-Lynch M, Kiermaier A, Eng-Wong J, Dang C (2018) Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol 29(3):646\u2013653. https:\/\/doi.org\/10.1093\/annonc\/mdx773","journal-title":"Ann Oncol"},{"issue":"12","key":"7785_CR8","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/s1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO, Oving IM, Honkoop AH, Tick LW, van de Wouw AJ, Mandigers CM, van Warmerdam LJ, Wesseling J, Vrancken Peeters MT, Linn SC, Sonke GS (2018) Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(12):1630\u20131640. https:\/\/doi.org\/10.1016\/s1470-2045(18)30570-9","journal-title":"Lancet Oncol"},{"issue":"7","key":"7785_CR9","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, W\u00fclfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380(7):617\u2013628. https:\/\/doi.org\/10.1056\/NEJMoa1814017","journal-title":"N Engl J Med"},{"issue":"2","key":"7785_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2):122\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa1703643","journal-title":"N Engl J Med"},{"issue":"22","key":"7785_CR11","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, Kuroi K, Im SA, Park BW, Kim SB, Yanagita Y, Ohno S, Takao S, Aogi K, Iwata H, Jeong J, Kim A, Park KH, Sasano H, Ohashi Y, Toi M (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376(22):2147\u20132159. https:\/\/doi.org\/10.1056\/NEJMoa1612645","journal-title":"N Engl J Med"},{"issue":"12","key":"7785_CR12","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1245\/s10434-014-3851-y","volume":"21","author":"S Ugras","year":"2014","unstructured":"Ugras S, Stempel M, Patil S, Morrow M (2014) Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement. Ann Surg Oncol 21(12):3780\u20133786. https:\/\/doi.org\/10.1245\/s10434-014-3851-y","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"7785_CR13","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/tbj.12276","volume":"20","author":"GM Freedman","year":"2014","unstructured":"Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ (2014) Risk of positive nonsentinel nodes in women with 1\u20132 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J 20(4):358\u2013363. https:\/\/doi.org\/10.1111\/tbj.12276","journal-title":"Breast J"},{"issue":"10","key":"7785_CR14","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1245\/s10434-009-0606-2","volume":"16","author":"L Wiechmann","year":"2009","unstructured":"Wiechmann L, Sampson M, Stempel M, Jacks LM, Patil SM, King T, Morrow M (2009) Presenting features of breast cancer differ by molecular subtype. Ann Surg Oncol 16(10):2705\u20132710. https:\/\/doi.org\/10.1245\/s10434-009-0606-2","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"7785_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3816\/CBC.2008.n.028","volume":"8","author":"SJ Crabb","year":"2008","unstructured":"Crabb SJ, Cheang MC, Leung S, Immonen T, Nielsen TO, Huntsman DD, Bajdik CD, Chia SK (2008) Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer 8(3):249\u2013256. https:\/\/doi.org\/10.3816\/CBC.2008.n.028","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"7785_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1245\/s10434-022-12357-8","volume":"30","author":"EA Mittendorf","year":"2023","unstructured":"Mittendorf EA, Kantor O, Weiss A, Richardson E, Garrido-Castro A, Portnow LH, Krop IE, Lin NU, Winer EP, Tolaney SM, King TA (2023) Nodal positivity in early-stage triple-negative breast cancer: implications for preoperative immunotherapy. Ann Surg Oncol 30(1):100\u2013106. https:\/\/doi.org\/10.1245\/s10434-022-12357-8","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"7785_CR17","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1245\/s10434-014-3989-7","volume":"21","author":"A Gangi","year":"2014","unstructured":"Gangi A, Mirocha J, Leong T, Giuliano AE (2014) Triple-negative breast cancer is not associated with increased likelihood of nodal metastases. Ann Surg Oncol 21(13):4098\u20134103. https:\/\/doi.org\/10.1245\/s10434-014-3989-7","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"7785_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1245\/s10434-022-12203-x","volume":"30","author":"MK Lee","year":"2023","unstructured":"Lee MK, Montagna G, Pilewskie ML, Sevilimedu V, Morrow M (2023) Axillary staging is not justified in postmenopausal clinically node-negative women based on nodal disease burden. Ann Surg Oncol 30(1):92\u201397. https:\/\/doi.org\/10.1245\/s10434-022-12203-x","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"7785_CR19","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1245\/s10434-016-5259-3","volume":"23","author":"A Mamtani","year":"2016","unstructured":"Mamtani A, Patil S, Van Zee KJ, Cody HS 3rd, Pilewskie M, Barrio AV, Heerdt AS, Morrow M (2016) Age and receptor status do not indicate the need for axillary dissection in patients with sentinel lymph node metastases. Ann Surg Oncol 23(11):3481\u20133486. https:\/\/doi.org\/10.1245\/s10434-016-5259-3","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"7785_CR20","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1245\/s10434-014-4090-y","volume":"22","author":"A Chung","year":"2015","unstructured":"Chung A, Gangi A, Mirocha J, Giuliano A (2015) Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery. Ann Surg Oncol 22(4):1128\u20131132. https:\/\/doi.org\/10.1245\/s10434-014-4090-y","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"7785_CR21","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1245\/s10434-024-14914-9","volume":"31","author":"CS Cortina","year":"2024","unstructured":"Cortina CS, Lloren JI, Rogers C, Johnson MK, Cobb AN, Huang CC, Kong AL, Singh P, Teshome M (2024) Does neoadjuvant chemotherapy in clinical T1\u2013T2 N0 triple-negative breast cancer increase the extent of axillary surgery? Ann Surg Oncol 31(5):3128\u20133140. https:\/\/doi.org\/10.1245\/s10434-024-14914-9","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"7785_CR22","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/cncr.34750","volume":"129","author":"A Weiss","year":"2023","unstructured":"Weiss A, Mart\u00ednez-S\u00e1ez O, Waks AG, Laws A, McGrath M, Tarantino P, Portnow L, Winer E, Rey M, Tapia M, Prat A, Partridge AH, Tolaney SM, Cejalvo JM, Mittendorf EA, King TA (2023) Nodal positivity and systemic therapy among patients with clinical T1\u2013T2N0 human epidermal growth factor receptor-positive breast cancer: results from two international cohorts. Cancer 129(12):1836\u20131845. https:\/\/doi.org\/10.1002\/cncr.34750","journal-title":"Cancer"},{"issue":"2","key":"7785_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/2229-516x.106353","volume":"2","author":"D Sethi","year":"2012","unstructured":"Sethi D, Sen R, Parshad S, Khetarpal S, Garg M, Sen J (2012) Histopathologic changes following neoadjuvant chemotherapy in various malignancies. Int J Appl Basic Med Res 2(2):111\u2013116. https:\/\/doi.org\/10.4103\/2229-516x.106353","journal-title":"Int J Appl Basic Med Res"},{"issue":"21","key":"7785_CR24","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1111\/bph.13725","volume":"174","author":"P Altieri","year":"2017","unstructured":"Altieri P, Murialdo R, Barisione C, Lazzarini E, Garibaldi S, Fabbi P, Ruggeri C, Borile S, Carbone F, Armirotti A, Canepa M, Ballestrero A, Brunelli C, Montecucco F, Ameri P, Spallarossa P (2017) 5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1. Br J Pharmacol 174(21):3713\u20133726. https:\/\/doi.org\/10.1111\/bph.13725","journal-title":"Br J Pharmacol"},{"issue":"8","key":"7785_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamaoncol.2022.1628","volume":"8","author":"G Montagna","year":"2022","unstructured":"Montagna G, Zhang J, Sevilimedu V, Charyn J, Abbate K, Gomez EA, Mehrara B, Morrow M, Barrio AV (2022) Risk factors and racial and ethnic disparities in patients with breast cancer-related lymphedema. JAMA Oncol 8(8):1195\u20131200. https:\/\/doi.org\/10.1001\/jamaoncol.2022.1628","journal-title":"JAMA Oncol"},{"issue":"2","key":"7785_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00520-018-4334-7","volume":"27","author":"JM Armer","year":"2019","unstructured":"Armer JM, Ballman KV, McCall L, Armer NC, Sun Y, Udmuangpia T, Hunt KK, Mittendorf EA, Byrd DR, Julian TB, Boughey JC (2019) Lymphedema symptoms and limb measurement changes in breast cancer survivors treated with neoadjuvant chemotherapy and axillary dissection: results of American College of Surgeons Oncology Group (ACOSOG) Z1071 (Alliance) substudy. Support Care Cancer 27(2):495\u2013503. https:\/\/doi.org\/10.1007\/s00520-018-4334-7","journal-title":"Support Care Cancer"},{"issue":"12","key":"7785_CR27","doi-asserted-by":"publisher","first-page":"7026","DOI":"10.1245\/s10434-023-13977-4","volume":"30","author":"K Huang","year":"2023","unstructured":"Huang K, Jakub J, Gabriel E, Moreno-Aspitia A, McLaughlin S (2023) Overall survival following neoadjuvant chemotherapy versus adjuvant chemotherapy in clinically node negative T1 triple negative breast cancer. Ann Surg Oncol 30(12):7026\u20137035. https:\/\/doi.org\/10.1245\/s10434-023-13977-4","journal-title":"Ann Surg Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07785-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07785-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T03:40:26Z","timestamp":1756438826000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07785-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["7785"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07785-5","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All other authors have no conflicts of interest disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of our Institutional Review Board. This article does not contain any studies with animals performed by any of the authors, has not been published before, is not under consideration for publication anywhere else, and has been approved for publication by all co-authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}